Procedure
APR-TD011 Spray for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase < 1
Chicago, Illinois
This trial is testing a special spray that cleans wounds on patients with a type of skin cancer called CTCL. The goal is to see if the spray is well-tolerated and if it changes the bacteria on the skin. The spray could help improve the condition of the skin lesions.
Popular Filters
Trials for Cutaneous T-Cell Lymphoma Patients
Tyrosine Kinase Inhibitor
Soquelitinib for Peripheral T-Cell Lymphoma
Recruiting2 awardsPhase 3
Burlingame, California
This trial is comparing a new drug called soquelitinib to the standard treatment chosen by the doctor for patients with certain types of relapsed or refractory peripheral T-cell lymphoma.
Protein-Drug Conjugate
Tagraxofusp for Blood Cancers
Recruiting1 awardPhase 1
Los Angeles, California
This trial is examining the safety of tagraxofusp, a novel agent that targets CD123, in pediatric patients with relapsed/refractory hematologic malignancies. The trial includes two parts: a monotherapy phase and a combination chemotherapy phase. The goal is to determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients.
Trials for Peripheral T-Cell Lymphoma Patients
Tyrosine Kinase Inhibitor
Soquelitinib for Peripheral T-Cell Lymphoma
Recruiting2 awardsPhase 3
Burlingame, California
This trial is comparing a new drug called soquelitinib to the standard treatment chosen by the doctor for patients with certain types of relapsed or refractory peripheral T-cell lymphoma.
Protein-Drug Conjugate
Tagraxofusp for Blood Cancers
Recruiting1 awardPhase 1
Los Angeles, California
This trial is examining the safety of tagraxofusp, a novel agent that targets CD123, in pediatric patients with relapsed/refractory hematologic malignancies. The trial includes two parts: a monotherapy phase and a combination chemotherapy phase. The goal is to determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients.
Trials With No Placebo
Tyrosine Kinase Inhibitor
Soquelitinib for Peripheral T-Cell Lymphoma
Recruiting2 awardsPhase 3
Burlingame, California
This trial is comparing a new drug called soquelitinib to the standard treatment chosen by the doctor for patients with certain types of relapsed or refractory peripheral T-cell lymphoma.
Protein-Drug Conjugate
Tagraxofusp for Blood Cancers
Recruiting1 awardPhase 1
Los Angeles, California
This trial is examining the safety of tagraxofusp, a novel agent that targets CD123, in pediatric patients with relapsed/refractory hematologic malignancies. The trial includes two parts: a monotherapy phase and a combination chemotherapy phase. The goal is to determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.